{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T01:17:02Z","timestamp":1779931022349,"version":"3.53.1"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Hematol Malig Rep"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1007\/s11899-021-00610-y","type":"journal-article","created":{"date-parts":[[2021,2,22]],"date-time":"2021-02-22T18:02:40Z","timestamp":1614016960000},"page":"72-81","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Immunotherapies Old and New: Hematopoietic Stem Cell Transplant, Chimeric Antigen Receptor T Cells, and Bispecific Antibodies for the Treatment of Relapsed\/Refractory Diffuse Large B Cell Lymphoma"],"prefix":"10.1007","volume":"16","author":[{"given":"Anupama","family":"Doraiswamy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mansi R.","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0770-644X","authenticated-orcid":false,"given":"Rajat","family":"Bannerji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,2,22]]},"reference":[{"issue":"4","key":"610_CR1","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1056\/NEJMoa011795","volume":"346","author":"B Coiffier","year":"2002","unstructured":"Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346(4):235\u201342.","journal-title":"N Engl J Med."},{"issue":"5","key":"610_CR2","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/S1470-2045(06)70664-7","volume":"7","author":"M Pfreundschuh","year":"2006","unstructured":"Pfreundschuh M, Trumper L, Osterborg A, Pettengell R, Trneny M, Imrie K, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol. 2006;7(5):379\u201391.","journal-title":"Lancet Oncol."},{"issue":"9880","key":"610_CR3","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1016\/S0140-6736(13)60313-X","volume":"381","author":"D Cunningham","year":"2013","unstructured":"Cunningham D, Hawkes EA, Jack A, Qian W, Smith P, Mouncey P, et al. Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles. Lancet. 2013;381(9880):1817\u201326.","journal-title":"Lancet."},{"issue":"21","key":"610_CR4","doi-asserted-by":"publisher","first-page":"1790","DOI":"10.1200\/JCO.18.01994","volume":"37","author":"NL Bartlett","year":"2019","unstructured":"\u2022\u2022 Bartlett NL, Wilson WH, Jung SH, Hsi ED, Maurer MJ, Pederson LD, et al. Dose-adjusted EPOCH-R compared with R-CHOP as frontline therapy for diffuse large B-cell Lymphoma: clinical outcomes of the phase III intergroup trial Alliance\/CALGB 50303. J Clin Oncol. 2019;37(21):1790\u20139 Phase 3 study showing no benefit of R-EPOCH compared to R-CHOP in treating DLBCL.","journal-title":"J Clin Oncol."},{"key":"610_CR5","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1056\/NEJMoa1301077","volume":"369","author":"PJ Stiff","year":"2013","unstructured":"Stiff PJ, Unger JM, Cook JR, Constine LS, Couban S, Stewart DA, et al. Autologous transplantation as consolidation for aggressive non-Hodgkin\u2019s lymphoma. N Engl J Med. 2013;369:1681\u201390.","journal-title":"N Engl J Med."},{"issue":"S2","key":"610_CR6","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1002\/hon.5_2629","volume":"37","author":"U Vitolo","year":"2019","unstructured":"Vitolo U, Witzig TE, Gascoyne RD, Scott DW, Zhang Q, Jurczak W, et al. ROBUST: first report of phase III randomized study of lenalidomide\/R-CHOP (R2-CHOP) vs placebo\/R-CHOP in previously untreated ABC-type diffuse large B-cell lymphoma. Hematological Oncology. 2019;37(S2):36\u20137.","journal-title":"Hematological Oncology."},{"issue":"15","key":"610_CR7","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1200\/JCO.18.02403","volume":"37","author":"A Younes","year":"2019","unstructured":"Younes A, Sehn LH, Johnson P, Zinzani PL, Hong X, Zhu J, et al. Randomized phase III trial of ibrutinib and rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in non-germinal center B-cell diffuse large B-cell lymphoma. J Clin Oncol. 2019;37(15):1285\u201395.","journal-title":"J Clin Oncol."},{"issue":"5","key":"610_CR8","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1016\/S1470-2045(18)30935-5","volume":"20","author":"A Davies","year":"2019","unstructured":"Davies A, Cummin TE, Barrans S, Maishman T, Mamot C, Novak U, et al. Gene-expression profiling of bortezomib added to standard chemoimmunotherapy for diffuse large B-cell lymphoma (REMoDL-B): an open-label, randomised. phase 3 trial. Lancet Oncol. 2019;20(5):649\u201362.","journal-title":"phase 3 trial. Lancet Oncol."},{"issue":"2","key":"610_CR9","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1002\/ajh.24615","volume":"92","author":"LJ Costa","year":"2017","unstructured":"Costa LJ, Maddocks K, Epperla N, Reddy NM, Karmali R, Umyarova E, et al. Diffuse large B-cell lymphoma with primary treatment failure: ultra-high risk features and benchmarking for experimental therapies. Am J Hematol. 2017;92(2):161\u201370.","journal-title":"Am J Hematol."},{"issue":"2","key":"610_CR10","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1038\/bmt.2016.213","volume":"52","author":"E Van Den Neste","year":"2017","unstructured":"Van Den Neste E, Schmitz N, Mounier N, Gill D, Linch D, Trneny M, et al. Outcomes of diffuse large B-cell lymphoma patients relapsing after autologous stem cell transplantation: an analysis of patients included in the CORAL study. Bone Marrow Transplant. 2017;52(2):216\u201321.","journal-title":"Bone Marrow Transplant."},{"issue":"23","key":"610_CR11","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1056\/NEJM199512073332305","volume":"333","author":"T Philip","year":"1995","unstructured":"Philip T, Guglielmi C, Hagenbeek A, Somers R, Van der Lelie H, Bron D, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin\u2019s lymphoma. N Engl J Med. 1995;333(23):1540\u20135.","journal-title":"N Engl J Med."},{"issue":"27","key":"610_CR12","doi-asserted-by":"publisher","first-page":"4184","DOI":"10.1200\/JCO.2010.28.1618","volume":"28","author":"C Gisselbrecht","year":"2010","unstructured":"Gisselbrecht C, Glass B, Mounier N, Singh Gill D, Linch DC, Trneny M, et al. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol. 2010;28(27):4184\u201390.","journal-title":"J Clin Oncol."},{"issue":"36","key":"610_CR13","doi-asserted-by":"publisher","first-page":"4462","DOI":"10.1200\/JCO.2012.41.9416","volume":"30","author":"C Gisselbrecht","year":"2012","unstructured":"Gisselbrecht C, Schmitz N, Mounier N, Singh Gill D, Linch DC, Trneny M, et al. Rituximab maintenance therapy after autologous stem-cell transplantation in patients with relapsed CD20(+) diffuse large B-cell lymphoma: final analysis of the collaborative trial in relapsed aggressive lymphoma. J Clin Oncol. 2012;30(36):4462\u20139.","journal-title":"J Clin Oncol."},{"issue":"31","key":"610_CR14","doi-asserted-by":"publisher","first-page":"4079","DOI":"10.1200\/JCO.2011.35.4423","volume":"29","author":"C Thieblemont","year":"2011","unstructured":"Thieblemont C, Briere J, Mounier N, Voelker HU, Cuccuini W, Hirchaud E, et al. The germinal center\/activated B-cell subclassification has a prognostic impact for response to salvage therapy in relapsed\/refractory diffuse large B-cell lymphoma: a bio-CORAL study. J Clin Oncol. 2011;29(31):4079\u201387.","journal-title":"J Clin Oncol."},{"issue":"31","key":"610_CR15","doi-asserted-by":"publisher","first-page":"3490","DOI":"10.1200\/JCO.2013.53.9593","volume":"32","author":"M Crump","year":"2014","unstructured":"Crump M, Kuruvilla J, Couban S, MacDonald DA, Kukreti V, Kouroukis CT, et al. Randomized comparison of gemcitabine, dexamethasone, and cisplatin versus dexamethasone, cytarabine, and cisplatin chemotherapy before autologous stem-cell transplantation for relapsed and refractory aggressive lymphomas: NCIC-CTG LY.12. J Clin Oncol. 2014;32(31):3490\u20136.","journal-title":"J Clin Oncol."},{"issue":"16","key":"610_CR16","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1182\/blood-2017-03-769620","volume":"130","author":"M Crump","year":"2017","unstructured":"Crump M, Neelapu SS, Farooq U, Van Den Neste E, Kuruvilla J, Westin J, et al. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood. 2017;130(16):1800\u20138.","journal-title":"Blood."},{"issue":"13","key":"610_CR17","doi-asserted-by":"publisher","first-page":"1662","DOI":"10.1200\/JCO.2012.45.9453","volume":"31","author":"JM Vose","year":"2013","unstructured":"Vose JM, Carter S, Burns LJ, Ayala E, Press OW, Moskowitz CH, et al. Phase III randomized study of rituximab\/carmustine, etoposide, cytarabine, and melphalan (BEAM) compared with iodine-131 tositumomab\/BEAM with autologous hematopoietic cell transplantation for relapsed diffuse large B-cell lymphoma: results from the BMT CTN 0401 trial. J Clin Oncol. 2013;31(13):1662\u20138.","journal-title":"J Clin Oncol."},{"issue":"16","key":"610_CR18","doi-asserted-by":"publisher","first-page":"2579","DOI":"10.1182\/blood-2014-10-606939","volume":"125","author":"CS Sauter","year":"2015","unstructured":"Sauter CS, Matasar MJ, Meikle J, Schoder H, Ulaner GA, Migliacci JC, et al. Prognostic value of FDG-PET prior to autologous stem cell transplantation for relapsed and refractory diffuse large B-cell lymphoma. Blood. 2015;125(16):2579\u201381.","journal-title":"Blood."},{"issue":"5","key":"610_CR19","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1111\/bjh.12176","volume":"160","author":"P Armand","year":"2013","unstructured":"Armand P, Welch S, Kim HT, LaCasce AS, Jacobsen ED, Davids MS, et al. Prognostic factors for patients with diffuse large B cell lymphoma and transformed indolent lymphoma undergoing autologous stem cell transplantation in the positron emission tomography era. Br J Haematol. 2013;160(5):608\u201317.","journal-title":"Br J Haematol."},{"issue":"2","key":"610_CR20","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1038\/s41409-019-0650-x","volume":"55","author":"E Gonzalez-Barca","year":"2020","unstructured":"Gonzalez-Barca E, Boumendil A, Blaise D, Trneny M, Masszi T, Finel H, et al. Outcome in patients with diffuse large B-cell lymphoma who relapse after autologous stem cell transplantation and receive active therapy. A retrospective analysis of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant. 2020;55(2):393\u20139.","journal-title":"Bone Marrow Transplant."},{"issue":"2","key":"610_CR21","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1111\/bjh.14046","volume":"174","author":"TS Fenske","year":"2016","unstructured":"\u2022\u2022 Fenske TS, Ahn KW, Graff TM, DiGilio A, Bashir Q, Kamble RT, et al. Allogeneic transplantation provides durable remission in a subset of DLBCL patients relapsing after autologous transplantation. Br J Haematol. 2016;174(2):235\u201348 Large retrospective registry study of allo-HSCT in patients who have progressed following auto-transplant.","journal-title":"Br J Haematol"},{"issue":"22","key":"610_CR22","doi-asserted-by":"publisher","first-page":"4411","DOI":"10.1002\/cncr.30895","volume":"123","author":"N Epperla","year":"2017","unstructured":"Epperla N, Maddocks KJ, Salhab M, Chavez JC, Reddy N, Karmali R, et al. C-MYC-positive relapsed and refractory, diffuse large B-cell lymphoma: impact of additional \u201chits\u201d and outcomes with subsequent therapy. Cancer. 2017;123(22):4411\u20138.","journal-title":"Cancer."},{"issue":"20","key":"610_CR23","doi-asserted-by":"publisher","first-page":"4619","DOI":"10.1182\/blood-2012-01-406033","volume":"119","author":"W Cuccuini","year":"2012","unstructured":"Cuccuini W, Briere J, Mounier N, Voelker HU, Rosenwald A, Sundstrom C, et al. MYC+ diffuse large B-cell lymphoma is not salvaged by classical R-ICE or R-DHAP followed by BEAM plus autologous stem cell transplantation. Blood. 2012;119(20):4619\u201324.","journal-title":"Blood."},{"issue":"3","key":"610_CR24","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1016\/j.bbmt.2017.11.023","volume":"24","author":"AF Herrera","year":"2018","unstructured":"Herrera AF, Rodig SJ, Song JY, Kim Y, Griffin GK, Yang D, et al. Outcomes after allogeneic stem cell transplantation in patients with double-hit and double-expressor lymphoma. Biol Blood Marrow Transplant. 2018;24(3):514\u201320.","journal-title":"Biol Blood Marrow Transplant."},{"issue":"8","key":"610_CR25","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.1080\/10428194.2017.1387905","volume":"59","author":"ZJ Roberts","year":"2018","unstructured":"Roberts ZJ, Better M, Bot A, Roberts MR, Ribas A. Axicabtagene ciloleucel, a first-in-class CAR T cell therapy for aggressive NHL. Leuk Lymphoma. 2018;59(8):1785\u201396.","journal-title":"Leuk Lymphoma."},{"issue":"1","key":"610_CR26","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1056\/NEJMoa1804980","volume":"380","author":"SJ Schuster","year":"2019","unstructured":"Schuster SJ, Bishop MR, Tam CS, Waller EK, Borchmann P, McGuirk JP, et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med. 2019;380(1):45\u201356.","journal-title":"N Engl J Med."},{"issue":"15_suppl","key":"610_CR27","doi-asserted-by":"publisher","first-page":"7505","DOI":"10.1200\/JCO.2018.36.15_suppl.7505","volume":"36","author":"JS Abramson","year":"2018","unstructured":"Abramson JS, Gordon LI, Palomba ML, Lunning MA, Arnason JE, Forero-Torres A, et al. Updated safety and long term clinical outcomes in TRANSCEND NHL 001, pivotal trial of lisocabtagene maraleucel (JCAR017) in R\/R aggressive NHL. J Clin Oncol. 2018;36(15_suppl):7505.","journal-title":"J Clin Oncol."},{"issue":"2","key":"610_CR28","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1038\/leu.2015.247","volume":"30","author":"D Sommermeyer","year":"2016","unstructured":"Sommermeyer D, Hudecek M, Kosasih PL, Gogishvili T, Maloney DG, Turtle CJ, et al. Chimeric antigen receptor-modified T cells derived from defined CD8+ and CD4+ subsets confer superior antitumor reactivity in vivo. Leukemia. 2016;30(2):492\u2013500.","journal-title":"Leukemia."},{"issue":"26","key":"610_CR29","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","volume":"377","author":"SS Neelapu","year":"2017","unstructured":"Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med. 2017;377(26):2531\u201344.","journal-title":"N Engl J Med."},{"issue":"1","key":"610_CR30","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","volume":"20","author":"FL Locke","year":"2019","unstructured":"Locke FL, Ghobadi A, Jacobson CA, Miklos DB, Lekakis LJ, Oluwole OO, et al. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial. Lancet Oncol. 2019;20(1):31\u201342.","journal-title":"Lancet Oncol."},{"issue":"26","key":"610_CR31","doi-asserted-by":"publisher","first-page":"2545","DOI":"10.1056\/NEJMoa1708566","volume":"377","author":"SJ Schuster","year":"2017","unstructured":"Schuster SJ, Svoboda J, Chong EA, Nasta SD, Mato AR, Anak O, et al. Chimeric antigen receptor T cells in refractory B-cell lymphomas. N Engl J Med. 2017;377(26):2545\u201354.","journal-title":"N Engl J Med."},{"issue":"15_suppl","key":"610_CR32","doi-asserted-by":"publisher","first-page":"7513","DOI":"10.1200\/JCO.2017.35.15_suppl.7513","volume":"35","author":"JS Abramson","year":"2017","unstructured":"Abramson JS, Palomba ML, Gordon LI, Lunning MA, Arnason JE, Forero-Torres A, et al. CR rates in relapsed\/refractory (R\/R) aggressive B-NHL treated with the CD19-directed CAR T-cell product JCAR017 (TRANSCEND NHL 001). J Clin Oncol. 2017;35(15_suppl):7513.","journal-title":"J Clin Oncol."},{"issue":"23","key":"610_CR33","doi-asserted-by":"publisher","first-page":"2106","DOI":"10.1182\/blood.2019004162","volume":"135","author":"SS Neelapu","year":"2020","unstructured":"Neelapu SS, Jacobson CA, Oluwole OO, Munoz J, Deol A, Miklos DB, et al. Outcomes of older patients in ZUMA-1, a pivotal study of axicabtagene ciloleucel in refractory large B-cell lymphoma. Blood. 2020;135(23):2106\u20139.","journal-title":"Blood."},{"issue":"2","key":"610_CR34","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1038\/s41577-018-0119-y","volume":"19","author":"CE Brown","year":"2019","unstructured":"Brown CE. Mackall CL. CAR T cell therapy: inroads to response and resistance. Nat Rev Immunol. 2019;19(2):73\u20134.","journal-title":"Nat Rev Immunol."},{"issue":"Supplement 1","key":"610_CR35","doi-asserted-by":"publisher","first-page":"4192","DOI":"10.1182\/blood-2018-99-111523","volume":"132","author":"CA Jacobson","year":"2018","unstructured":"Jacobson CA, Locke FL, Miklos DB, Herrera AF, Westin JR, Lee J, et al. End of phase 1 results from Zuma-6: axicabtagene ciloleucel (Axi-Cel) in combination with atezolizumab for the treatment of patients with refractory diffuse large B cell lymphoma. Blood. 2018;132(Supplement 1):4192.","journal-title":"Blood."},{"key":"610_CR36","doi-asserted-by":"publisher","first-page":"146","DOI":"10.3389\/fonc.2019.00146","volume":"9","author":"NN Shah","year":"2019","unstructured":"Shah NN, Maatman T, Hari P, Johnson B. Multi targeted CAR-T cell therapies for B-cell malignancies. Front Oncol. 2019;9:146.","journal-title":"Front Oncol."},{"issue":"14","key":"610_CR37","first-page":"1632","volume":"136","author":"C Tong","year":"2020","unstructured":"Tong C, Zhang Y, Liu Y, Ji X, Zhang W, Guo Y, et al. Optimized tandem CD19\/CD20 CAR-engineered T cells in refractory\/relapsed B-cell lymphoma. Blood. 2020;136(14):1632\u201344.","journal-title":"Blood."},{"issue":"Supplement_1","key":"610_CR38","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1182\/blood-2019-122724","volume":"134","author":"KM Ardeshna","year":"2019","unstructured":"Ardeshna KM, Marzolini MAV, Norman J, Al-Hajj M, Thomas S, Faulkner J, et al. Phase 1\/2 study of AUTO3 the first bicistronic chimeric antigen receptor (CAR) targeting CD19 and CD22 followed by an anti-PD1 in patients with relapsed\/refractory (r\/r) diffuse large B cell lymphoma (DLBCL): results of cohort 1 and 2 of the Alexander study. Blood. 2019;134(Supplement_1):246.","journal-title":"Blood."},{"issue":"18","key":"610_CR39","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1016\/S1359-6446(05)03554-3","volume":"10","author":"E Wolf","year":"2005","unstructured":"Wolf E, Hofmeister R, Kufer P, Schlereth B, Baeuerle PA. BiTEs: bispecific antibody constructs with unique anti-tumor activity. Drug Discov Today. 2005;10(18):1237\u201344.","journal-title":"Drug Discov Today."},{"issue":"11","key":"610_CR40","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1182\/blood-2015-06-651380","volume":"127","author":"A Viardot","year":"2016","unstructured":"\u2022\u2022 Viardot A, Goebeler ME, Hess G, Neumann S, Pfreundschuh M, Adrian N, et al. Phase 2 study of the bispecific T-cell engager (BiTE) antibody blinatumomab in relapsed\/refractory diffuse large B-cell lymphoma. Blood. 2016;127(11):1410\u20136 Multicenter experience with single-agent blinatumomab for R\/R DLBCL.","journal-title":"Blood"},{"issue":"Supplement_1","key":"610_CR41","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1182\/blood-2019-122451","volume":"134","author":"R Bannerji","year":"2019","unstructured":"\u2022\u2022 Bannerji R, Allan JN, Arnason JE, Brown JR, Advani RH, Barnes JA, et al. Clinical activity of REGN1979, a bispecific human, anti-CD20 x anti-CD3 antibody, in patients with relapsed\/refractory (R\/R) B-cell non-Hodgkin lymphoma (B-NHL). Blood. 2019;134(Supplement_1):762 First-in-human phase 1 study of odronextamab (REGN 1979).","journal-title":"Blood"},{"issue":"Supplement_1","key":"610_CR42","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1182\/blood-2019-123742","volume":"134","author":"SJ Schuster","year":"2019","unstructured":"\u2022\u2022 Schuster SJ, Bartlett NL, Assouline S, Yoon S-S, Bosch F, Sehn LH, et al. Mosunetuzumab induces complete remissions in poor prognosis non-Hodgkin lymphoma patients, including those who are resistant to or relapsing after chimeric antigen receptor T-cell (CAR-T) therapies, and is active in treatment through multiple lines. Blood. 2019;134(Supplement_1):6 ASH 2019 Plenary presentation of the mosunetuzumab dose finding study.","journal-title":"Blood"},{"issue":"Supplement 1","key":"610_CR43","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1182\/blood-2018-99-110207","volume":"132","author":"M Hutchings","year":"2018","unstructured":"Hutchings M, Iacoboni G, Morschhauser F, Offner F, Sureda A, Salles GA, et al. CD20-Tcb (RG6026), a novel \u201c2:1\u201d format T-cell-engaging bispecific antibody, induces complete remissions in relapsed\/refractory B-cell non-Hodgkin\u2019s lymphoma: preliminary results from a phase I first in human trial. Blood. 2018;132(Supplement 1):226.","journal-title":"Blood."},{"issue":"Supplement_1","key":"610_CR44","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1182\/blood-2019-121460","volume":"134","author":"P Lugtenburg","year":"2019","unstructured":"Lugtenburg P, Mous R, Clausen MR, Chamuleau MED, Johnson P, Linton K, et al. First-in-human, phase 1\/2 trial to assess the safety and clinical activity of subcutaneous GEN3013 (DuoBody\u00ae-CD3\u00d7CD20) in B-cell non-Hodgkin lymphomas. Blood. 2019;134(Supplement_1):758.","journal-title":"Blood."},{"issue":"18","key":"610_CR45","doi-asserted-by":"publisher","first-page":"2493","DOI":"10.1200\/JCO.2010.32.7270","volume":"29","author":"MS Topp","year":"2011","unstructured":"Topp MS, Kufer P, G\u00f6kbuget N, Goebeler M, Klinger M, Neumann S, et al. Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. J Clin Oncol. 2011;29(18):2493\u20138.","journal-title":"J Clin Oncol."},{"issue":"36","key":"610_CR46","doi-asserted-by":"publisher","first-page":"4134","DOI":"10.1200\/JCO.2014.56.3247","volume":"32","author":"MS Topp","year":"2014","unstructured":"Topp MS, G\u00f6kbuget N, Zugmaier G, Klappers P, Stelljes M, Neumann S, et al. Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia. J Clin Oncol. 2014;32(36):4134\u201340.","journal-title":"J Clin Oncol."},{"issue":"10","key":"610_CR47","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1200\/JCO.2014.59.1586","volume":"34","author":"ME Goebeler","year":"2016","unstructured":"Goebeler ME, Knop S, Viardot A, Kufer P, Topp MS, Einsele H, et al. Bispecific T-cell engager (BiTE) antibody construct blinatumomab for the treatment of patients with relapsed\/refractory non-Hodgkin lymphoma: final results from a phase I study. J Clin Oncol. 2016;34(10):1104\u201311.","journal-title":"J Clin Oncol."},{"issue":"16","key":"610_CR48","doi-asserted-by":"publisher","first-page":"2491","DOI":"10.1182\/bloodadvances.2019000025","volume":"3","author":"V Dufner","year":"2019","unstructured":"Dufner V, Sayehli CM, Chatterjee M, Hummel HD, Gelbrich G, Bargou RC, et al. Long-term outcome of patients with relapsed\/refractory B-cell non-Hodgkin lymphoma treated with blinatumomab. Blood Adv. 2019;3(16):2491\u20138.","journal-title":"Blood Adv."},{"key":"610_CR49","doi-asserted-by":"publisher","DOI":"10.1038\/srep17943","volume":"5","author":"EJ Smith","year":"2015","unstructured":"Smith EJ, Olson K, Haber LJ, Varghese B, Duramad P, Tustian AD, et al. A novel, native-format bispecific antibody triggering T-cell killing of B-cells is robustly active in mouse tumor models and cynomolgus monkeys. Sci Rep. 2015;5:17943.","journal-title":"Sci Rep."},{"issue":"287","key":"610_CR50","doi-asserted-by":"publisher","first-page":"287ra70","DOI":"10.1126\/scitranslmed.aaa4802","volume":"7","author":"LL Sun","year":"2015","unstructured":"Sun LL, Ellerman D, Mathieu M, Hristopoulos M, Chen X, Li Y, et al. Anti-CD20\/CD3 T cell-dependent bispecific antibody for the treatment of B cell malignancies. Sci Transl Med. 2015;7(287):287ra70.","journal-title":"Sci Transl Med"},{"issue":"8","key":"610_CR51","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1158\/2159-8290.CD-18-0297","volume":"8","author":"CY Slaney","year":"2018","unstructured":"Slaney CY, Wang P, Darcy PK. Kershaw MH. CARs versus BiTEs: a comparison between T cell-redirection strategies for cancer treatment. Cancer Discov. 2018;8(8):924\u201334.","journal-title":"Cancer Discov."},{"issue":"4","key":"610_CR52","doi-asserted-by":"publisher","first-page":"e77","DOI":"10.1016\/j.bbmt.2019.12.771","volume":"26","author":"P Dreger","year":"2020","unstructured":"Dreger P, Fenske TS, Montoto S, Pasquini MC, Sureda A, Hamadani M. Cellular immunotherapy for refractory diffuse large B cell lymphoma in the chimeric antigen receptor-engineered T cell era: still a role for allogeneic transplantation? Biol Blood Marrow Transplant. 2020;26(4):e77\u201385.","journal-title":"Biol Blood Marrow Transplant."},{"issue":"4","key":"610_CR53","doi-asserted-by":"publisher","first-page":"648","DOI":"10.3324\/haematol.2018.206177","volume":"104","author":"R Davide","year":"2019","unstructured":"Davide R, Valeria S, Alessio B, Gianluca G. Liquid biopsy in lymphoma. Haematologica. 2019;104(4):648\u201352.","journal-title":"Haematologica."},{"issue":"Supplement 1","key":"610_CR54","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1182\/blood-2018-99-118344","volume":"132","author":"LE Budde","year":"2018","unstructured":"Budde LE, Sehn LH, Assouline S, Flinn IW, Isufi I, Yoon S-S, et al. Mosunetuzumab, a full-length bispecific CD20\/CD3 antibody, displays clinical activity in relapsed\/refractory B-cell non-Hodgkin lymphoma (NHL): interim safety and efficacy results from a phase 1 study. Blood. 2018;132(Supplement 1):399.","journal-title":"Blood."},{"issue":"15_suppl","key":"610_CR55","doi-asserted-by":"publisher","first-page":"3048","DOI":"10.1200\/jco.2013.31.15_suppl.3048","volume":"31","author":"B Wu","year":"2013","unstructured":"Wu B, Hijazi Y, Wolf A, Brandl C, Sun Y-N, Zhu M. Pharmacokinetics (PK) of blinatumomab and its clinical implications. J Clin Oncol. 2013;31(15_suppl):3048.","journal-title":"J Clin Oncol."}],"container-title":["Current Hematologic Malignancy Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-021-00610-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11899-021-00610-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-021-00610-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,29]],"date-time":"2023-01-29T14:30:33Z","timestamp":1675002633000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11899-021-00610-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":55,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["610"],"URL":"https:\/\/doi.org\/10.1007\/s11899-021-00610-y","relation":{},"ISSN":["1558-8211","1558-822X"],"issn-type":[{"value":"1558-8211","type":"print"},{"value":"1558-822X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2]]},"assertion":[{"value":"1 February 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 February 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Anupama Doraiswamy and Mansi R. Shah declare no potential conflicts of interest.Rajat Bannerji reports research funding from AbbVie, Regeneron, F. Hoffmann-La Roche\/Genentech, and Pharmacyclics. His spouse is employed by Sanofi-Pasteur.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}]}}